UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Tebentafusp: a first-in-class treatment for metastatic uveal melanoma

Howlett, Sarah; Carter, Thomas J; Shaw, Heather M; Nathan, Paul D; (2023) Tebentafusp: a first-in-class treatment for metastatic uveal melanoma. Therapeutic Advances in Medical Oncology , 15 10.1177/17588359231160140. Green open access

[thumbnail of howlett-et-al-2023-tebentafusp-a-first-in-class-treatment-for-metastatic-uveal-melanoma.pdf]
Preview
Text
howlett-et-al-2023-tebentafusp-a-first-in-class-treatment-for-metastatic-uveal-melanoma.pdf - Published Version

Download (616kB) | Preview

Abstract

Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell receptor targeting a gp100 epitope presented by human leukocyte antigen-A*02:01 cells, fused to an anti-CD3 single-chain variable fragment. Tebentafusp is both the first bispecific T-cell engager to show efficacy in the treatment of advanced solid cancer and the first anti-cancer treatment to demonstrate an overall survival benefit in patients with uveal melanoma (UM). This review article will focus on the clinical development of tebentafusp, the mechanism of action and resultant evolution of the management of advanced UM.

Type: Article
Title: Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/17588359231160140
Publisher version: https://doi.org/10.1177/17588359231160140
Language: English
Additional information: © The Author(s), 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, gp100, ImmTAC, metastatic, tebentafusp, uveal melanoma, PHASE-II TRIAL, PD-L1 EXPRESSION, PATIENTS PTS, OPEN-LABEL, MULTICENTER, IPILIMUMAB, SURVIVAL, NIVOLUMAB, EFFICACY, GEMCITABINE
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: https://discovery.ucl.ac.uk/id/eprint/10176321
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item